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A B S T R A C T
Special attention is required when pharmacological treatment is indicated for a pregnant woman. P-glycoprotein
(MDR1) is a well-known transporter localized in the maternal blood-facing apical membrane of placental syn-
cytiotrophoblast and is considered to play an important role in protecting the developing fetus. Maraviroc, a
MDR1 substrate that is registered for treatment of HIV infection, shows a low toxicity profile, suggesting fa-
vorable tolerability also if administered to pregnant women. Nevertheless, there is only poor understanding to
date regarding the extent to which it permeates across the placental barrier and what are the transport me-
chanisms involved. Endeavoring to clarify the passage of maraviroc across placenta, we used in this study the
method of closed-circuit perfusion of maraviroc across human placental cotyledon. The data obtained confirmed
slight involvement of MDR1, but they also suggest possible interaction with other transport system(s) working in
the opposite direction from that of MDR1. Complementary in vitro studies, including cellular experiments on
choriocarcinoma BeWo cells as well as transporter-overexpressing MDCKII and A431 cell lines and accumulation
in placental fresh villous fragments, revealed maraviroc transport by MRP1, OATP1A2, and OATP1B3 trans-
porters. Based on mRNA expression data in the placental tissue, isolated trophoblasts, and fetal endothelial cells,
especially MRP1 and OATP1A2 seem to play a crucial role in cooperatively driving maraviroc into placental
tissue. By the example of maraviroc, we show here the important interplay of transporters in placental drug
handling and its possibility to overcome the MDR1-mediated efflux.
1. Introduction
Research over the past few decades has made it clear that placenta
should no longer be viewed as a mechanistic barrier between mother
and fetus. Considerable progress has been made in understanding the
transport role of this essential organ for maintaining pregnancy. In
parallel with ensuring that nutrition is supplied to the developing tis-
sues, the placenta needs to handle waste products and protect the fetus
against potentially toxic xenobiotics, including drugs, which might be
present in maternal blood. Several transport proteins and carriers have
been described in the placenta that mediate active and facilitated
transfer of nutrients and other essential compounds in the maternal-to-
fetal direction [1–3]. On the other hand, most of the xenobiotics are
lipophilic in their structures and to some extent able to permeate the
placenta by passive diffusion [4]. ATP-dependent transporters P-gly-
coprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP,
ABCG2) present in the maternal blood-facing apical microvillous
membrane of the trophoblast layer have the capability to efflux
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potentially harmful compounds to the maternal blood and thereby
protect the fetus [5–7]. These membrane transporters also constitute
possible sites for drug–drug interactions. Therefore, the ability of any
therapeutic compound to be transported by membrane proteins or to
cause their inhibition needs to be assessed and drug–drug interactions
considered, as emphasized by the International Transporter Consortium
[8,9] and such global drug regulatory authorities as the U.S. Food and
Drug Administration (FDA) and European Medicines Agency [10,11]. In
the placenta, MDR1 and BCRP have been indicated to protect the fetus
against various lipophilic drugs, including, for example, glyburide, di-
goxin, and vinca alkaloids [12–14]. In general, most of the drugs that
are identified as MDR1 or BCRP substrates in vitro are assumed to be
compromised in their transfer to fetus. Compared to MDR1 or BCRP,
less is known about the placental multidrug resistant proteins (MRPs)
transporters, among which MRP2 (ABCC2) and MRP1 (ABCC1) seem to
be the most-expressed members of this subfamily. While MRP2 shows
the same localization as do MDR1 and BCRP, and, similarly to these two
transporters, it is believed to ensure efflux in the fetal-to-maternal di-
rection [15], MRP1 has been detected mainly on the basal membrane of
trophoblast and fetal endothelial cells [16–19].
In addition to the ABC drug efflux transporter family, the solute
carriers (SLC) also are able to interact with drugs and their inhibition
may lead to clinically relevant drug–drug interactions [20–22]. Several
members of the organic anion-transporting polypeptide (OATP) and
organic carnitine (OCTNs) uptake transporters are recognized for their
roles in placental handling of various endogenous compounds, in-
cluding L-carnitine [23,24]. Among these, mainly OATP2A1, OATP4A1
[25,26], and OCTN2 [27] have been described in the apical micro-
villous membrane of human placenta, while OATP2B1 seems to ensure
influx through the opposite, basal membrane of trophoblast cells [28].
In addition to these carriers, lower expression of several other OATP
members, e.g., OATP1A2, OATP1B3, and OATP3A1 [29–31], and
OCTN1 [32] also has been reported in human placenta.
Many antiretroviral compounds have recently been identified as
substrates of MDR1 and/or BCRP in vitro [33–36], thus demonstrating
that placental ABC transporters-mediated drug–drug interactions might
affect drug levels in fetal circulation [37]. In particular, administration
of antiretroviral therapy to ideally all HIV-positive pregnant women is a
much-discussed topic, because it decreases the risk of mother-to-child
viral transfer from 45 % down to 1–2% or less [38,39]. Although the
approach to the treatment is itself becoming more modern and effec-
tive, the introduction of newer drugs for use during pregnancy is
scarcely advancing, and traditional therapeutics with well-known
toxicity and safety profiles are preferred in order to avoid potential
harmful effects to the fetus. Interestingly, however, a recent study
comparing a recommended combination of three common anti-
retroviral drugs with an alternative variant showed no significant dif-
ference in incidence of adverse birth outcomes [40].
The chemokine receptor 5 (CCR5) inhibitor maraviroc blocks HIV
from binding to the host cells and, due to its low toxicity, it has been
approved not only for use in adults infected by the R5-tropic virus but
also for the treatment of children [41]. Because sufficiently conclusive
results are still lacking, however, maraviroc is not yet recommended in
antiretroviral pharmacotherapy schedules for pregnant women [39].
Nevertheless, several case reports seem to be optimistic as they describe
births of healthy, uninfected neonates of women exposed to maraviroc
during pregnancy [42]. Importantly, the chemokine system plays a key
role in the control of inflammatory and immune processes. Therefore, in
addition to controlling HIV, maraviroc seems to bring therapeutic
benefit also in non-AIDS related comorbidities – e.g. atherosclerosis
[43] – and is considered as well in several off-label indications, in-
cluding multiple sclerosis, rheumatoid arthritis, and some cancer in-
dications [44–46].
In a very recent study, we identified maraviroc as a substrate of
human MDR1 in vitro. Employing in situ dually perfused rat term pla-
centa, significant rat Mdr1-mediated efflux of the drug to the maternal
compartment was observed, although this was subsequently abolished
in the presence of MDR1/Mdr1 inhibitors [47]. The primary aim of this
study was to address the protective role of MDR1 in the transfer of
maraviroc across human placenta using the well-established model of
closed-circuit perfusion of maraviroc across a single intact placental
cotyledon. Based on the results indicating possible interplay of several
other transport systems in the placenta that compromise the fetal-to-
maternal efflux mediated by MDR1, we subsequently employed several
ex vivo and in vitro studies in human placental tissue and relevant cell
lines in order to identify the contributing transport mechanisms.
2. Material and methods
2.1. Human placentas
Placentas from normal pregnancies were collected at the
Department of Obstetrics and Gynecology, Medical University of Graz
and used immediately after delivery or caesarean section. All women
were medication-free and negative for HIV and hepatitis B or C. The
study was approved by the institutional ethical committee (no. 24-529
ex 11/12) and informed consent was provided by all participants in-
volved in the study. The placentas for experiments in villous fragments
were collected at the Faculty Hospital Hradec Kralove after delivery
following uncomplicated pregnancies. Written informed consent was
obtained as approved by the local research Ethics Committee (approval
no. 201006S15 P).
2.2. Cell lines and generation of cell-based carrier systems
The human choriocarcinoma BeWo cell line, clone b30 was kindly
provided by Prof. Christiane Albrecht (University of Bern, Switzerland)
with kind permission from Dr. Alan Schwartz (Washington University,
USA). Madin-Darby Canine Kidney II (MDCKII) cell lines, both parental
and overexpressing human MRP1 transporter, were obtained from Dr.
A. Schinkel (Netherlands Cancer Institute, Amsterdam, Netherlands).
Human epidermal cell lines A431, both control and overexpressing
human OATP1A2, -1B3, -2A1, -2B1, or -3A1 transporters, were gener-
ated in the laboratories of the Institute of Enzymology (RCNS, Hungary)
according to well-established protocols. Plasmid constructs of SLCO2B1
and -1B3 were prepared and introduced in order to create the A431-
OATP2B1 and -1B3 cell lines as described previously [48]. OATP1A2
overexpression was achieved as described by Bakos et al. [49]. A431
cell lines overexpressing OATP2A1, OATP3A1, or OATP4A1 were
constructed as part of the current study. Briefly, the cDNA of human
SLCO2A1 (BC041140, plasmid ID:HsCD00338568, Harvard Plasmid
Repository) was PCR-amplified using Phusion® High-Fidelity PCR Kit
(NEB, Ipswitch, MA, US) and the following primers: forward 5′ GTAA
ATGCGGCCGCAAGAATTCGCCACCATGGGACCCAGGATAGG and re-
verse 5′ GTACATGCGGCCGCTAAGCTTTCACACTCGGGAATCCTC. The
PCR fragment was cloned between the NotI HindIII sites of the pSB
vector [48]. The cDNAs of SLCO3A1 and SLCO4A1 were amplified from
the pAcUW-21-L/OATP3A1 and pAcUW-21-L/OATP4A1 vectors [50]
with the following primers: 3A1 forward 5′ TAAAGGATCCGCGGCCG
CGCCACCATGCAGGGGAAGAAGCCG, 3A1 reverse 5 ′ CATGTCTCGAG
ACTAGTAAGCTTCTATAAAACGGACTCCATG, 4A1 forward 5′ TAAAG
GATCCGCCACCATGAAGAGCGCCAAAGGT, and 4A1 reverse 5′ CATG
TAACTAGTTCACCCTTCTTTTACTATTTTG. PCR fragments were di-
gested with BamHI and SpeI enzymes (NEB) and were cloned into the
corresponding sites of the pRRL-CMV-MCS-IRES-ΔCD4 vector [48]. The
base order of the cDNAs in all constructs was verified by sequencing.
Empty pRRLΔCD4 or pSB vectors were used as negative controls. In the
case of OATP2A1, A431 cells (ATCC) were transfected using a Fugene
HD reagent (Promega, Madison, WI, USA.) according to the supplier’s
protocol and as described by [48.]. SLCO3A1 or SLCO4A1 over-
expression in A431 cells was achieved by lentiviral transduction [48].
Protein expression of all cloned OATPs in the particular cell lines was
L. Tupova, et al. Biomedicine & Pharmacotherapy 129 (2020) 110506
2
confirmed by western blotting analysis (data not shown).
All cell lines were cultivated in antibiotic-free, complete high-glu-
cose Dulbecco’s Modified Eagle’s Medium (DMEM) with L-glutamine,
supplemented with 10 % fetal bovine serum at 37 °C with 5% CO2 and
regularly tested for Mycoplasma contamination. Cells from passages
5–20 for the MDCKII and A431 cell lines and passages from 5 to 15 for
the BeWo cells were used in the experiments. Dimethyl sulfoxide con-
centrations in all the assays did not exceed 0.5 %.
2.3. Chemicals and reagents
Radiolabeled maraviroc ([3H]-MVC) was purchased from Moravek
Biochemicals (Brea, CA, USA). DMEM, fetal bovine serum, sodium do-
decyl sulfate (SDS), calcein-AM, dextran from Leuconostoc spp. (Mr ≈
40,000), phosphate buffered saline (PBS), and scintillation cocktail
were bought from Sigma–Aldrich (St. Louis, Missouri, USA). Opti-
MEM®, reduced serum medium, Cascade Blue hydrazide, and the bi-
cinchoninic acid (BCA) assay were obtained from Thermo Fisher
Scientific. Maraviroc and ritonavir were provided by the NIH AIDS
Reagent Program or purchased from MedChemExpress (Monmouth
Junction, NJ, USA), which was also the source of control inhibitors
elacridar (GF120918), zosuquidar (LY335979), verapamil, sulfasala-
zine, L-carnitine, and MK-571. All the salts necessary for preparation of
perfusion and Thyrode’s buffers were purchased from Merck
(MerckGroup, Germany), and fluorescein-methotrexate triammonium
salt was from Biotium (Hayward, CA, USA).
2.4. Ex vivo perfusion of human placenta
The ex vivo placental perfusion setup used herein has been described
previously [51–53] and was adapted for the current study. Briefly,
within 30min after delivery, a single unimpaired cotyledon was se-
lected and the supplying chorionic artery and vein pair was cannulated
and immediately rinsed with perfusion medium (DMEM:Earls buffer
3:1; containing 15 g/L dextran, 2 g/L glucose, and 250mg/mL amox-
icillin; Sigma–Aldrich). Prepared cotyledon was placed in the middle of
a perfusion chamber and the fetal arterial cannula was connected to a
perfusion medium reservoir (37 °C). The maternal circulation was es-
tablished by insertion of three rounded needles into the intervillous
space of the cotyledon. Constant fetal (3 mL/min) and maternal (9 mL/
min) artery inflows were generated using a magnetic pump (Codan,
Salzburg, Austria). Flow recovery of the fetal circulation was≥ 95 % in
all experiments. In order to approximate in utero oxygen levels, fetal
perfusion medium was pretreated with a gas mixture (95 % N2, 5%
CO2) through a gas-exchange device (Living Systems, St. Albans, VT,
USA) during the experiment. The back-flow pressure in the fetal vas-
cular system was recorded in line during the experiment by a micro
catheter pressure sensor (Millar, Houston, TX, USA) inserted into the
fetal arterial cannula.
2.4.1. Settings of perfusion experiments
The experimental time slots were set based on the findings from
other, similar experiments evaluating the contribution of ABC trans-
porters to placental drug transfer [13]. A single perfusion experiment
setup was initiated with a 90min fetal and maternal closed-circuit
period when maraviroc (600 ng/mL) was added to both circulations
(minutes 0–90). This was followed by 30min washout with maraviroc-
free media (minutes 90–120), 30min of inhibitor pre-incubation
(minutes 120–150), and 90min of maraviroc with MDR1 inhibitors
elacridar (2 μM) or ritonavir (10 μM) (minutes 150–240), all applied to
both compartments. Samples were taken every 30min from fetal vein
and maternal artery in volume of 1.5 mL. Samples were centrifuged to
separate perfusate from the remaining blood elements or residual tissue
and stable isotopically labelled internal standard (SIL-IS) of maraviroc
(100 ng/mL, maraviroc D6, TRC, Canada) was added into 1mL of clear
supernatant. Completed samples were stored at −80 °C in a freezer
until analysis. After the experiment period, tissue integrity was tested
by a 30min open-circuit antipyrine period. Antipyrine concentration
was determined by high-performance liquid chromatography (HPLC-
UV) in accordance with the protocol by [54] in maternal and fetal
perfusates. Only perfusion experiments reaching fetal-to-maternal an-
tipyrine ratios ≥ 0.3 within 30min in a fetal open circuit were con-
sidered as successful experiments and were further processed.
2.4.2. Analysis of maraviroc in perfusates
The determination of maraviroc in placental perfusion medium was
carried out using the Acquity Ultra Performance LC (UPLC) system
(Waters, Milford, MA, USA) coupled with a Micromass Quattro micro
API benchtop triple quadrupole mass spectrometer (Waters,
Manchester, UK). Samples of 2 μL were injected onto an Acquity BEH
C18 analytical column (50× 2.1mm i.d.; particle size 1.7 μm). The
analytes were separated using gradient elution with 0.1 % aqueous
formic acid (eluent A) and acetonitrile (eluent B) at a flow rate of
0.35mL/min. The gradient started with 5% of eluent B in A, and it was
increased to 95 % B in 3min. The percentage of eluent B was reduced to
the original conditions of 5% at 3.1 min. The total time of chromato-
graphic separation, including column equilibration, was 5min.
Quantification of analyte was achieved via selected reaction monitoring
using the precursor ion [M+H]+ with m/z=514.1 and two selected
fragment ions including quantifier m/z=388.9 and qualifier ion m/
z=280.0 to increase method selectivity. Ion source parameters were
set up as follows: capillary voltage – 1.0 kV, extractor – 3.0 V, RF lens –
0.1 V, ion source temperature – 130 °C, cone voltage – 35 V. The des-
olvation gas (nitrogen) flow was 1,000 L/h and temperature 450 °C.
Nitrogen was also used as a cone gas with a flow rate of 100 L/h.
Collision energy was set individually for each selected reaction mon-
itoring transition at 20 eV (514.1 → 388.9) and at 30 eV (514.1 →
280.0). The data was acquired using MassLynx 4.1 software and pro-
cessed by QuanLynx. The sample concentrations of maraviroc reported
in ng/mL were converted into percentages of the respective initial stock
solution concentration (100 %).
The pretreatment of 200 μL perfusion samples involved liquid–li-
quid extraction using dichloromethane in a 1:2 (v/v) ratio as an ex-
traction agent. The sample was agitated (1400 rpm, 30 °C, 10min) and
centrifuged (14,000 rpm, 4 °C, 5min). Subsequently, 400 μL of extract
was taken, evaporated to dryness using nitrogen, and reconstituted in
20 % acetonitrile. The samples containing maraviroc were quantified
using a matrix calibration curve and SIL-IS.
2.4.3. Detection of maraviroc metabolites
To determine whether maraviroc may be metabolized by human
placenta tissue during perfusion experiments, detailed screening for
maraviroc metabolites was performed. Presence of metabolites was
screened using a UHPLC-HRMS (high-resolution mass spectrometry)
method. The Acquity UPLC I-class (Waters, USA) UHPLC system was
coupled to a Synapt G2Si (Waters, UK) of q-TOF type. Chromatography
was carried out using an Acquity UPLC BEH C18 (50× 2.1mm, 1.7 μm)
column and gradient elution with acetonitrile and 0.1 % formic acid in
water. Maraviroc is believed predominantly to be metabolized to var-
ious hydroxy metabolites by oxidation on phenyl or difluorocyclohexyl
rings and to a few decomposition products [55,56]. The m/z value
530.3301 of protonated molecule and its possible adducts were sear-
ched using reconstructed ion chromatograms (mass tolerance 10 ppm)
in electrospray ionization-positive mode corresponding to the summary
formula of C29H41F2N5O2. For the decomposition products, the che-
mical formulae C13H22N4O and C13H22N4 were expected [55] and the
m/z of 251.1866 and 235.1917 for protonated molecules were searched
together with possible adducts. The column temperature was kept at
40 °C and autosampler temperature at 10 °C. High-resolution, fullscan
measurements were carried out in electrospray positive ion mode in the
range of 50 to 1,200 m/z. The ion source conditions were set up as
follows: capillary voltage – 0.8 kV, sampling cone voltage – 40 V, source
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offset – 80 V, source temperature – 120 °C, desolvation temperature –
600 °C, desolvation gas flow – 500 L/h, cone gas flow – 50 L/h, and
nebulizer gas flow – 6 bar. Leucine enkephalin was used as a lock mass
reference for internal calibration and sodium formate for external ca-
libration. MassLynx 4.1 software was used for data acquisition.
2.5. Isolation of trophoblast and fetoplacental endothelial cells from human
term placenta
Endothelial cells were isolated from arterial vessels dissected from
the apical surface of the chorionic plate of human healthy-term pla-
centa following the protocol published by [57]. Arterial endothelial
cells were cultivated in a 75 cm2 cultivation flask until confluence (4–5
days), then harvested for RNA isolation.
The primary trophoblast cells were isolated from four human term
placentas after uncomplicated pregnancy and delivery. Rinsed villous
placental tissue was digested by a mixture of trypsin and DNAse I and
the released cells were captured at the top of the percoll gradient. After
the centrifuging step, cells were purified using immunomagnetic beads
conjugated with MCA-81 antibody against HLA-A, B, and C (Serotec,
Puchheim, Germany) [58]. Trophoblast cells were seeded into 75 cm2
flasks (23×106), cultivated for 48 h, then isolated using an RNeasy
Mini Kit (Qiagen, Hilden, Germany).
2.6. RNA isolation, reverse transcription, and quantitative PCR analysis
A piece of tissue was sampled from each perfused placenta and
processed for subsequent use in detecting gene expression of selected
placental transporters. In order to evaluate the contribution of tro-
phoblast cells and fetal endothelial cells to the expression, these cells
were isolated from placental tissue as described above and subjected to
the RT-qPCR analysis. Thereby, we verified the mRNA expression of
relevant transporters in BeWo cells. TriReagent (Molecular Research
Center, Cincinnati, OH, USA) and Gb Reverse Transcription Kit (Generi
Biotech, Hradec Kralove, Czech Republic) were used for RNA isolation
and reverse transcription following the manufacturer’s instructions. The
cDNA samples thusly obtained were evaluated by PCR using TaqMan®
Universal Master Mix II without uracil-N-glycosylase (Thermo Fisher
Scientific) and predesigned TaqMan® Real Time Expression PCR assays
for human ABCB1 (Hs00184500_m1), ABCC1 (Hs01561483_m1),
SLCO1A2 (Hs00366488_m1), SLCO1B3 (Hs00251986_m1), SLCO2A1
(Hs01114926_m1), SLCO2B1 (Hs01030343_m1), SLCO3A1
(Hs00203184_m1), and SLCO4A1 (Hs00249583_m1) (Applied
Biosystems, Thermo Fisher Scientific USA) and then analyzed using the
QuantStudio™ 6 system (Thermo Fisher Scientific). Each sample was
amplified in triplicate using the following PCR cycling profile: 95 °C for
10min, followed by 40 cycles at 95 °C for 15 s and 60 °C for 60 s.
Expression levels are reported as number of gene copies per μg of
transcribed RNA based on a five-point concentration calibration curve
of a randomly chosen comparator placental sample. This sample was
also analyzed for the number of gene copies using droplet digital PCR
assay as described previously [59]. Briefly, the ddPCR™ Supermix for
Probes (Bio-Rad, Hercules, CA, USA) and the predesigned TaqMan as-
says (Thermo Fisher Scientific) stated above were used. The analysis
was performed using the QX200 Droplet Generator, T100™ Thermal
Cycler, and QX200™ Droplet Reader, all from BioRad. According to the
number of positive droplets compared to negative, the concentration of
each of the target genes was calculated using the QuantaSoft™ Software.
Only wells in which the number of droplets exceeded 13,000 were used.
Knowing the number of copies of each target gene (expressed as
number of transcripts/μL RNA) in our comparator placental sample, the
numbers of gene transcripts in all the other cDNA samples were de-
duced by performing a qPCR analysis in which the five-point con-
centration curve of the calibrator cDNA was present.
2.7. Bidirectional transport assays across monolayers of MDCKII-MRP1,
MDCKII-parental, and BeWo cell lines
Transport assays across monolayers of MDCKII-MRP1 and parental
cells were carried out as described previously [60,61]. MRP1 cells were
seeded at density 0.6×106 cells on 12-well, 3 μM microporous poly-
carbonate membrane filters (Transwell 3402; Costar Corning, New
York, NY, USA) and cultured for 72 h to confluence.
Transport assays employing monolayers of BeWo cells were per-
formed based on a modified protocol originated from Crowe et al. [62]
using microporous polycarbonate membrane filters (0.4 μm pore size,
12mm diameter; Transwell 3401; Costar Corning) coated previously
with human placental collagen (Sigma–Aldrich). BeWo cells were
seeded at density 0.1×106 per insert and cultured for 6 days (37 °C
/5% CO2) with daily replacement of cell culture medium. The transe-
pithelial electrical resistance (TEER) was measured using a Millicell®
ERS Voltohmmeter (Millipore, Merck) prior to each experiment.
On the day of an experiment, cell monolayers were rinsed with PBS
(37 °C), then pre-incubated for 15min in Opti-MEM with/without the
control inhibitors elacridar (2 μM), ritonavir (10 μM), or MK-571 (50
μM). Due to transport of maraviroc by endogenous canine Mdr1 [47], a
certain part of the experiments in MDCKII cells were run in the presence
of the Mdr1 inhibitor zosuquidar (2 μM), which does not interact with
human MRP1 [63]. The assay was started by the addition of [3H]-MVC
0.2 μCi/mL (65 nM) into the apical or basal compartment with regular
sampling from the opposite compartment.
Transport of [3H]-MVC was detected by liquid scintillation counting
and expressed as percentages calculated from measured values relative
to the stock solution. The efflux ratio (ER=PappB-A/PappA–B) was
calculated within a linear period from values of permeable coefficients
(Papp) reached after 2 h of incubation.
Semipermeable membranes were cut out from each well, and cell
monolayer was lysed in 0.02 % SDS after the experiment. The accu-
mulation of [3H]-MVC in cells was measured and standardized to total
protein.
2.8. Accumulation assay in BeWo and A431 cell lines
BeWo and A431 cells overexpressed -OATP1A2, -1B3, -2A1, -2B1,
-3A1, or -4A1 and their appropriate controls were seeded onto a 24-well
plate (Techno Plastic Products, Trasadingen, Switzerland) at density
0.3×106 cells per well and cultured for 24 h (A431) or 48 h (BeWo) at
37 °C in 5% CO2. On the day of an experiment, the culture medium was
removed and cells were rinsed with PBS (37 °C). The BeWo cells were
then incubated for 15min with Opti-MEM with and without the in-
hibitors elacridar (2 μM), ritonavir (10 μM), verapamil (100 μM), L-
carnitine (1mM), MK-571 (50 μM), and cold maraviroc at a high con-
centration (100 μM). In the case of A431 cells, an uptake buffer con-
sisting of 125mM NaCl, 4.8mM KCl, 1.2mM CaCl2, 1.2 mM KH2PO4,
12mM MgSO4, 5.6 mM D-glucose, and 1M HEPES (pH 7.4) was pre-
pared and sulfasalazine (100 μM) was used as a control inhibitor.
Accumulation was initiated by the addition of [3H]-MVC 0.2 μCi/mL
(65 nM) and stopped after 30min (A431) or 60min (BeWo) by re-
moving the supernatant. The cells were immediately washed two times
with ice-cold PBS (4 °C) and subsequently lysed in 0.2 % SDS.
Maraviroc accumulation was measured by liquid scintillation counting
of the lysates and normalized to protein levels. None of the applied
inhibitory drugs affected viability of the cells, as confirmed by mon-
itoring the cellular confluency and protein content in each well at the
end of experiment.
2.9. Inhibitory assays on MRP1-mediated efflux and OATP1B3 and
OATP1A2 influx
In order to determine whether maraviroc, elacridar, or ritonavir
inhibit MRP1, OATP1B3, or OATP1A2 transporters, the following
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inhibitory assays were performed:
Inhibitory assay in MDCKII-MRP1 was run as described previously
[47]. Cells were seeded on 96-well plates at density 5× 104 and in-
cubated to full confluence. A preincubation period (15min) either in
pure Opti-MEM or in the presence of a range of maraviroc, ritonavir,
and elacridar concentrations (1–50 μM) or control MRP1 inhibitor MK-
571 (50 μM) preceded an experimental period. The assay was initiated
by addition of the fluorescent MRP1 substrate calcein-AM (10 μM).
Relative fluorescent units were measured in 1min intervals for 30min,
at constant temperature 37 °C, using a Genios Plus microplate reader
(Tecan, Salzburg, Austria). Efflux response was expressed as the per-
centage of the concentration at which full inhibition was reached or as a
percentage inhibitory effect of model inhibitor. IC50 values were de-
termined by nonlinear regression analysis using data fitted onto data
points by the GraphPad Prism 8.2.0 program (GraphPad Software Inc.,
La Jolla, CA, USA).
Similarly, inhibitory assays were performed on OATP-over-
expressing A431 cells as described previously [48]. Briefly, cells grown
on 96-well plates were pre-incubated with increasing amounts of in-
hibitors for 5min at 37 °C. The assay was started by the addition of
fluorescein-methotrexate (1 μM) for 15min in the case of OATP1A2 or
of Cascade Blue (10 μM) for 30min in that of OATP1B3. After several
washings with PBS, fluorescence was measured using an EnSpire®
fluorescent plate reader (PerkinElmer, Waltham, MA, USA). Uptake
rates were expressed as percentages of uptakes measured in the absence
of any inhibitor. IC50 values were determined by nonlinear regression
analysis using data fitted on data points by the GraphPad Prism 8.2.0
program.
2.10. Maraviroc accumulation assay in fresh villous fragments of human
placenta
The study was conducted based on the method developed by SL
Greenwood (University of Manchester, UK) and as described previously
[35,64,65]. Briefly, 4–5 cubes (1 cm3) of fresh placental villous tissue
were dissected from placenta and rinsed two times in a mixture (1:1) of
DMEM and Tyrode’s buffer (pH 7.4). Small, fresh villous fragments
were cut out and fixed with thread on metal hooks, immersed into
DMEM/Tyrode’s solution to equilibrate (37 °C), and then transferred
into pre-incubating solutions of elacridar (2 μM), ritonavir (10 μM),
MK-571 (50 μM), and sulfasalazine (100 μM) for 10min. Accumulation
assay was initiated by transfer of fragments into Tyrode’s buffer con-
taining [3H]-MVC 0.2 μCi/mL (65 nM) with and without inhibitors. The
assay was stopped after 10, 30, 90, 120, or 180min by twice-washing
fragments in non-radioactive solutions of Tyrode’s buffer. The frag-
ments were then soaked in distilled water for at least 15 h to lyse the
surface trophoblast layer and release accumulated radioactivity. Fi-
nally, the placental tissue fragments were cut from the hooks and lysed
in 0.3 M NaOH for 10 h at 37 °C. The released radioactive maraviroc
was quantified by liquid scintillation counting and normalized to total
protein levels using the BCA assay. Additional experiments addressing
the possible formation of maraviroc metabolites in the villous tissue
were performed by exposing fragments to maraviroc (600 ng/mL),
corresponding to the concentration used in placental perfusion study.
UHPLC-HRMS analysis for maraviroc metabolites was then performed
in the lysates comprising the water solution after 15 h lysis of fragments
and in the lysates of the remaining fragmental tissue.
2.11. Statistical analysis
The data obtained are presented as means ± standard deviations
(SD) of at least three independent experiments. Statistical analysis was
performed using GraphPad Prism software version 8.2.0 (GraphPad
Software). The p-values were calculated by one-way ANOVA or non-
parametric Mann–Whitney test and considered as statistically sig-
nificant if p≤ 0.05.
3. Results
3.1. Dual perfusion of human placenta cotyledon
Dual perfusion of human placenta cotyledon in the closed-circuit
setup was first performed to verify the contribution of MDR1-mediated
efflux to transplacental permeability of maraviroc as the transporter’s
substrate. After the initial 30min of perfusion, levels of maraviroc
dropped to 86.7 % in the fetal compartment and 73.7 % on the maternal
side. The maraviroc levels remained then rather stable on both pla-
cental sides, showing, however, slight tendency to increase in the fetal
compartment up to 94.9 % at 90min (Fig. 1A) while slowly decreasing
to 69.4 % at 90min on the maternal side (Fig. 1B). Both added MDR1
inhibitors, elacridar and ritonavir, prevented a drop of maraviroc levels
in the fetal compartment (Fig. 1A) but did so only slightly in the ma-
ternal compartment (Fig. 1B).
Low concentrations of maraviroc were also found in perfusates at
the end of washout (minutes 90–120) and during pre-incubation
(minutes 120–150), with slightly higher levels in the maternal com-
partment. Therefore, faster washout of maraviroc retained in the pla-
cental tissue to the maternal circuit is suggested.
No maraviroc metabolites were detected in either the perfusion
samples with/without inhibitors or the lysates from fresh villous frag-
ments exposed to maraviroc solutions, thus indicating that the drug was
not metabolized during experiments and therefore biotransformation is
not responsible for observed changes in maraviroc concentrations in
perfusion assays.
3.2. Bidirectional transport and accumulation of maraviroc in BeWo cells
Following the perfusion studies, transport of maraviroc across po-
larized monolayer of BeWo choriocarcinoma cell line lacking MDR1
expression (Table 1) was employed. Both MDR1 inhibitors, elacridar (2
μM) and ritonavir (10 μM), were added with the intent to evaluate
possible contributions of placental transport systems other than MDR1
Fig. 1. Transport of maraviroc across human placental
cotyledon. A, B: Maraviroc (600 ng/mL), shown here
as 100 %, was perfused in a closed-circuit setup with
the same initial concentration in both fetal (A) and
maternal (B) compartments. Drop of maraviroc levels
was observed in both compartments within the first
90min of the perfusion experiment. Addition of MDR1
inhibitors elacridar (GF, 2 μM) and ritonavir (RIT, 10
μM) prevented decrease in maraviroc levels on the
fetal but not maternal side (150–240min) compared to
the non-inhibited phase. Time periods 90–120min and
120–150min depict the washout and pre-incubation
phases, respectively. Data are presented as
means ± SD (n≥ 3) and analyzed by Mann–Whitney
test (*p≤ 0.05).
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in uptake and/or efflux of maraviroc. The data shows accelerated
maraviroc transport in apical-to-basolateral (A–B) relative to baso-
lateral-to-apical (B-A) direction and with ER value of 0.70 (Fig. 2A).
Addition of elacridar significantly decreased A–B transport from
20.8%–17.7% (p < 0.05) while not affecting the B-A direction, thus
resulting in ER value of 0.80 (Fig. 2B). Very interesting activity was
observed in the case of ritonavir, which also reduced A–B transport to
16.7 % (p < 0.05) but increased also B-A transport from
14.5%–22.1%, resulting in ER = 1.39. The primarily preferred direc-
tion of maraviroc transfer across BeWo monolayer was thus reversed
(Fig. 2C). These results strongly supported the theory of one or more
other transporters being involved in maraviroc transport across pla-
cental barrier.
Following transport assay, the simple accumulation study in BeWo
cells was carried out with the aim of helping to identify the mechanisms
contributing to maraviroc permeability (Fig. 2D). Decrease in mar-
aviroc accumulation (2.5-fold) was observed when a high concentration
of unlabeled maraviroc (100 μM) was applied, thus indicating satura-
tion of a transporter-mediated uptake of maraviroc to the cells rather
than its efflux. The accumulation of maraviroc in the cells also sig-
nificantly decreased in the presence of 100 μM verapamil (4.07-fold),
10 μM ritonavir (2.63-fold), and 2 μM elacridar (1.45-fold), suggesting
inhibition of an uptake transporter. On the contrary, enhanced (1.95-
fold) accumulation was detected in the presence of the ABCCs inhibitor
MK-571 (50 μM), indicating inhibition of MRPs transporter-mediated
maraviroc efflux. The fact that no effect of L-carnitine (1mM) was ob-
served on maraviroc accumulation excludes a contribution of OCTN1/2
transporters.
3.3. Gene expression of evaluated transporters
A detailed quantitative analysis of mRNA transporter expression for
all perfused placentas and BeWo cells along with independent samples
from isolated trophoblasts and fetal endothelial cells is summarized in
Table 1. As expected, ABCB1 was detected in all perfused placentas but
not in BeWo cells, while ABCC1 was markedly expressed in placentas
and also in BeWo. SLCO2A1, SLCO2B1, SLCO3A1, and SLCO4A1 were
substantially expressed in all the perfused placentas, although a rather
lower number of transcripts was detected for SLCO1A2 and this was
only negligible for SLCO1B3. BeWo cells showed high levels of
SLCO4A1 and SLCO1A2 transcripts. Expression analysis of in-
dependently isolated trophoblast and fetal endothelial cells showed
presence of all evaluated transporters with the exception of SLCO1B1,
with transcript levels being about one order of magnitude higher for
ABCB1, SLCO1A2, SLCO1B3, and SLCO2B1 in trophoblast than in fetal
endothelial cells. Similar substantial levels of ABCC1, SLCO4A1, and
SLCO2A1 mRNA transcripts were found in trophoblast and fetal en-
dothelial cells.
Table 1
mRNA gene expression of studied transporters.
Transporter gene Placentas Endothelial cells Trophoblast cells BeWo cells
ABCB1 8.5× 103 (0.08–1.7× 104) 0.7×102 (0.3–1.4× 102) 2.3× 103 (0.16–6.4×103) n.d.
ABCC1 4.1× 103 (0.05–1.1× 104) 4.9×103 (4.2–6.3× 103) 5.3× 103 (0.16–1.1×104) 2.3× 103 (1.8–3.1×103)
SLCO1A2 6.3× 102 (0.4–6.9× 103) 2.9×102 (2.4–7.7× 102) 1.2× 103 (0.03–3.4×103) 3.6× 103 (1.5–4.9×103)
SLCO1B1 n.d. n.d. n.d. n.d.
SLCO1B3 0.4× 102 (0.1 – 0.8×102) 0.1×102 (0.02–1.2× 102) 1.2× 102 (0.91–1.4×102) n.d.
SLCO2A1 9.0× 103 (0.2–2.4× 104) 3.6×103 (1.6–6.7× 103) 7.6× 103 (0.21–2.6×104) 5.4× 102 (3.5–8.1×102)
SLCO2B1 1.1× 104 (0.12–2.8× 104) 0.6×102 (0.4 – 0.9× 102 1.5× 103 (0.12–1.7×104) 9.7× 102 (8.3–16.0× 102)
SLCO3A1 1.0× 103 (0.44–2.1× 103) 6.7×102 (1.1–2.5× 102) 3.3× 103 (0.06–3.5×103) 4.1× 102 (2.5–4.7×102)
SLCO4A1 3.1× 103 (0.14–1.2× 104) 9.2×103 (0.32–1.4× 104) 1.6× 103 (0.65–4.2×103) 1.8× 104 (1.7–1.9×104)
Data is presented as median (inter-quartile range) of number of gene copies/μg of transcribed mRNA; n.d. = not detected.
Fig. 2. Bidirectional transport and uptake stu-
dies of [3H]-MVC (65 nM) in BeWo chor-
iocarcinoma cell line. A: Uninhibited transport
of [3H]-MVC showing acceleration in apical-to-
basolateral (▼;A-B) direction. B: Effect of
elacridar (GF, 2 μM) on [3H]-MVC transport
showing significant decrease in A-B direction
without affecting the (▲; B-A) transport C:
Transport of [3H]-MVC in the presence of ri-
tonavir (RIT, 10 μM) showing decrease in A-B
direction while increasing the B-A transport D:
Effect of high (saturable) concentration of
maraviroc (MVC-S, 100 μM), verapamil (VER,
100 μM), ritonavir (RIT, 10 μM), elacridar (GF,
2 μM), and MK-571 (MK, 50 μM) on accumu-
lation of [3H]-MVC in BeWo cells. Data are
presented as means ± SD (n ≥ 3). Statistical
significance was evaluated by one-way ANOVA
or Mann–Whitney test (*p≤ 0.05, ***p≤
0.001).
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3.4. Maraviroc is a substrate of human MRP1
Following through on the evidence from data obtained in previous
experiments, interaction of [3H]-MVC (65 nM, 0.2 μCi/mL) with human
MRP1 was studied in MDCKII cells. These cells show overexpression of
human MRP1 transporter in the basolateral membrane [61], which
accelerates the transfer of its substrates from the apical to the baso-
lateral compartment. As shown in Fig. 3B, maraviroc is readily trans-
ported through MDCKII parental cells from the basolateral to the apical
side (ER=5.50) by the function of the endogenous Mdr1 transporter
[47]. On the other hand, there is no significant basolateral-to-apical
transport of maraviroc in MDCKII-MRP1 cells (ER= 1.01), as shown in
Fig. 3A. This data results in the high relative ratio (Rr= ERparental/
ERMRP1) of 5.44 when comparing transport in the two tested cell lines
and reveals maraviroc to be a substrate of human MRP1. Addition of
zosuquidar (2 μM) showed significant increase in accumulation of
maraviroc within monolayers of MDCKII-parental cells, thus reflecting
inhibition of endogenous Mdr1. This effect could not be observed in
MDCKII-MRP1 due to the retained efflux activity of non-inhibited
MRP1 pumping maraviroc out of the cells. Dual addition of zosuquidar
and the MRP1 inhibitor MK-571 (50 μM) resulted in significant increase
in maraviroc accumulation within both cell lines (Fig. 3C).
3.5. Maraviroc is a substrate of human OATP1A2 and OATP1B3 but not of
OATP2A1, 2B1, 3A1, or 4A1
In vitro uptake of [3H]-MVC (65 nM, 0.2 μCi/mL) was measured in
A431 cells overexpressing human placental OATP transporters
OATP1A2, OATP1B3, OATP2A1, OATP2B1, OATP3A1, or OATP4A1
and compared to the respective mock control cells (Fig. 4A). Sig-
nificantly increased levels of maraviroc were detected in A431-
OATP1A2 (1.68-fold) and A431-OATP1B3 (2.21-fold) cells, thereby
indicating that maraviroc is a substrate of these transporters. No dif-
ference in accumulation of maraviroc was observed in the OATP2A1-,
OATP2B1-, OATP3A1-, or OATP4A1-expressing cells. Decrease of
maraviroc accumulation in the presence of the OATP inhibitor sulfa-
salazine (SLF, 100 μM) in A431-OATP1B3 (Fig. 4B) or -OATP1A2
(Fig. 4C) cells further confirms that maraviroc is a transported substrate
of these two OATPs.
3.6. Accumulation inhibitory assay
Because earlier experiments had revealed maraviroc to be a sub-
strate of MRP1, OATP1A2, and OATP1B3, we further aimed to verify
whether the inhibitors elacridar and ritonavir that were used during
placental perfusions (Fig. 1) and in BeWo transport and accumulation
assays (Fig. 2) could (in addition to MDR1) also affect these transpor-
ters.
We found that ritonavir increases accumulation of calcein-AM in
MDCKII-MRP1 cells with maximal inhibitory potency at 50 μM and
IC50= 13.9 μM (Fig. 5A). No changes were observed in the calcein-AM
accumulation when elacridar or maraviroc were present (tested con-
centration range was 1–50 μM).
Inhibitory effects of ritonavir, elacridar, and maraviroc toward
OATP1A2 or OATP1B3 transporters appear as a decrease of fluorescein-
methotrexate or Cascade-Blue hydrazide accumulation in A431-
OATP1A2 and A431-OATP1B3 cells, respectively. Ritonavir and ela-
cridar revealed inhibitory activity toward OATP1A2 (IC50 of 3.70 μM
and 1.21 μM, respectively), while only weak OATP1A2 inhibition
(IC50= 72.9 μM) was calculated for maraviroc (Fig. 5B). Ritonavir re-
vealed also potent inhibition of OATP1B3 (IC50= 0.82 μM) in A431-
OATP1B3 cells. The same effect was observed with elacridar
(IC50= 3.17 μM). Maraviroc exhibited no inhibition of OATP1B3
transport, but a low level of activation (37 %) could be observed at high
maraviroc concentrations (Fig. 5C).
The inhibition of OATP1A2- and OATP1B3-mediated uptake and
MRP1-mediated efflux of maraviroc by ritonavir and elacridar was
subsequently confirmed in accumulation assays using inhibitory con-
centrations corresponding to those from the dually perfused human
placenta experiments (Fig. 5D).
3.7. Uptake of maraviroc into fresh villous fragments of human term
placenta
Fresh fragments prepared from human placental villous tissue re-
flect primarily the situation in the maternal-facing syncytiotrophoblast
Fig. 3. Transport of [3H]-MVC (65 nM) across
monolayer of MDCKII-MRP1 and -parent cells.
A, B: Basolateral-to-apical (▲; B-A) transport
and apical-to-basolateral (▼; A-B) transport of
[3H]-MVC across MDCKII-MRP1 (A) and
MDCKII-parental (B) cells was determined.
Efflux ratio (ER) was calculated based on
permeable coefficient (Papp) values reached
after 2 h of the transport. C: Effect of Mdr1
inhibitor zosuquidar (LY, 2 μM) and control
MRP1 inhibitor MK-571 (MK, 50 μM) on mar-
aviroc accumulation in MDCKII-parental and
MDCKII-MRP1 cells. D: Depiction of en-
dogenous Mdr1 and human MRP1, both inter-
acting with maraviroc in MDCKII and MDCKII-
MRP1 cellular models.
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layer (Fig. 6D). Accumulation of maraviroc measured in placental
fragments bathed in [3H]-MVC (65 nM) solution showed increase over
time (up to 120min; Fig. 6A). Elacridar (2 μM) and ritonavir (10 μM)
were added for 30min (Fig. 6B) and 90min (Fig. 6C). Neither of these
showed significant effect on accumulation of maraviroc. When more
specific OATPs and MRP1 inhibitors, sulfasalazine (100 μM) and MK-
571 (50 μM), respectively, were added, significant changes in mar-
aviroc accumulation were observed (Fig. 6B, C)
4. Discussion
More than 10 years have passed since maraviroc was registered by
FDA as the first selective blocker of CCR5 receptor for the treatment of
R5-tropic HIV-infected adults. During this period, further study of
maraviroc’s safety and efficiency has produced favorable results and
enabled expansion of the drug’s usage also to HIV-infected children
[41,66]. Due to the unique mechanism of action targeting CCR5, the
intense placental expression of which is closely linked to the higher risk
of mother-to-child transmission of HIV, and owing to its expected
therapeutic benefit also in other non-HIV related indications, it seems
probable that maraviroc will more frequently be administered to
pregnant women [43–45,67]. Detailed knowledge is therefore needed
regarding transplacental transfer of maraviroc and the mechanisms
involved. Maraviroc is a quite lipophilic compound (logP= 5.80) [68]
and is presumed to cross biological membranes easily via passive dif-
fusion. We have recently described this antiretroviral as a substrate of
human MDR1 and, using a rat placental model, demonstrated the role
for rat Mdr1 in preventing maraviroc’s penetration from mother to fetus
[47]. A possible contribution of ABC transporters in placental handling
of maraviroc in humans has already been suggested by a study showing
accelerated fetal-to-maternal clearance of maraviroc in an open-circuit
perfusion setup, albeit without providing any direct proof, such as by
pharmacological inhibition [69]. Here, we employed dual ex vivo per-
fusion of a human placental cotyledon in a closed-circuit setup, which
limits transfer of drug via passive diffusion and emphasizes transporters
activity. The contribution of placental MDR1 was demonstrated
through rapid drop of maraviroc concentration on the fetal side after
30min of perfusion (Fig. 1A), which was prevented by the MDR1 in-
hibitors ritonavir (10 μM) and elacridar (2 μM). To the best of our
knowledge, this is the first time that functional involvement of human
MDR1 has been shown in maraviroc distribution across placental bar-
rier. Based on the known active efflux capability of the microvillous
membrane, the amount of maraviroc transferred from the fetal com-
partment would be expected to appear on the maternal side. On the
contrary, even more-pronounced decline in maraviroc levels was ob-
served in the maternal circulation, and no significant increase was
observed with the presence of inhibitor (Fig. 1B). The decline in mar-
aviroc concentration on both sides of perfused placenta raised the
question as to where does the escaping maraviroc appear? Having ex-
cluded possible adherence of maraviroc to the perfusion tubes and other
plastic lab ware, we checked also for the occurrence of known mar-
aviroc metabolites in perfusates and homogenized placental tissue.
Although maraviroc has been described as a subject of biotransforma-
tion through CYP3A4 and CYP3A5 isoenzymes in the liver [70,71], no
maraviroc metabolites were detected in our perfusates or tissue lysates,
reflecting probably the too-low biotransformation activity of placental
tissue [72] and a too-short perfusion time of the tissue to enable sig-
nificant formation of metabolites.
The unexpected behavior of maraviroc during the human placental
perfusions and partly hidden effect of MDR1-mediated efflux differ
considerably from observation in rat placenta, where we had described
robust contribution of rat Mdr1 in transplacental transfer of maraviroc,
correlating also with only low levels of maraviroc (less than 2%) re-
tained in rat placental tissue [47]. Unlike the findings in rat, maraviroc
seems to be retained within the human placenta, as up to 10 % of the
maraviroc was released from the tissue to the perfusates (in particular
in maternal compartment) after pre-incubation periods, when placenta
was perfused by maraviroc-free buffer with inhibitors. These observa-
tions from human placenta perfusions thereby indicate the involvement
of some other storage and/or transport mechanism(s) in placental
handling of maraviroc.
In order to identify those membrane transporters possibly con-
tributing to the placental handling of maraviroc and diminishing the
impact of MDR1-mediated maraviroc efflux as shown in the ex vivo
placenta perfusion study, several cell-based models were employed.
Because the human choriocarcinoma BeWo cell line mimics placental
trophoblast layer in vitro but shows no expression of ABCB1 [5,17 and
Table 1], it served as an ideal model for fast, initial screening (Fig. 2).
Among the applied inhibitors, MK-571, inhibiting efflux provided by
MRP transporters, significantly increased maraviroc accumulation in
BeWo cells. Based on the accelerated transport of maraviroc in the
apical-to-basolateral direction across polarized monolayers of BeWo
cells, the basolaterally located MRP1 was suggested as the MRP trans-
porter most probably involved. Indeed, subsequent transport assays
across the monolayers of MDCKII-MRP1 cells revealed maraviroc to be
a MRP1 substrate (Fig. 3).
Complementary accumulation studies in MDCKII-MRP1 cells
(Fig. 3C) further revealed high preference of maraviroc for MRP1- ra-
ther than endogenous canine Mdr1-mediated efflux, which drives the
transport in the opposite direction. This observation leads to a very
interesting conclusion in the context of our recent study, wherein we
describe a much stronger tendency for maraviroc to interact with the
canine endogenous Mdr1 variant than with human MDR1 transporter in
MDCKII-MDR1 cells [47]. Considering these two findings and the fact
that transport experiments in MDCKII-MDR1 cells in our previous study
and in MDCKII-MRP1 here were carried out under the identical
Fig. 4. [3H]-MVC (65 nM) uptake in A431 cells over-
expressing human OATP transporters -1A2, -1B3,
-2A1, -2B1, -3A1, and -4A1. A: Tested cell lines were
incubated in the presence of [3H]-MVC for 30min and
maraviroc accumulation values reached were com-
pared with results in control cell lines. B, C: Effect of
OATP inhibitor sulfasalazine (SLF, 100 μM) on mar-
aviroc transport mediated by OATP1A2 or -1B3. Data
are presented as means ± SD (n ≥ 4). Statistical
significance was evaluated by Mann–Whitney test
(*p≤ 0.05, **p≤ 0.01).
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protocol, we can suggest rather higher affinity of maraviroc to human
MRP1 than to human MDR1.
Interestingly, when a high concentration of maraviroc (100 μM) was
applied in BeWo cells, it led to significant decrease in maraviroc
accumulation, thus indicating saturation of uptake rather than an efflux
transport mechanism. Similar decrease of maraviroc uptake was ob-
served also with the application of nonspecific inhibitors ritonavir and
verapamil. Published data showing maraviroc affinity to human
Fig. 5. Inhibitory assay in MDCKII-MRP1, A431-OATP1A2, and -1B3 cells. A: Changes in accumulation of fluorescent MRP1 substrate calcein-AM in MDCKII-MRP1
cells in the presence of tested inhibitors maraviroc, ritonavir, and elacridar. B: Effect of maraviroc, elacridar, and ritonavir on fluorescein-methotrexate uptake in
A431-OATP1A2 cells. C: Uptake of Cascade Blue hydrazide in A431-OATP1B3 in presence of maraviroc, ritonavir, and elacridar. D: Effect of elacridar (GF, 2 μM) and
ritonavir (RIT, 10 μM) on accumulation of [3H]-MVC (65 nM) in MDCKII-MRP1, A431-OATP1A2 and -1B3 cells. Data are presented as means ± SD (n ≥ 3).
Statistical significance was evaluated by one-way ANOVA and Mann–Whitney test (*p≤ 0.05, **p≤ 0.01, ***p≤ 0.001).
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OATP1B1 [73] and maraviroc-induced inhibition of uptake of the
nonspecific OATPs fluorescent substrate 8-(2-[fluoresceinyl]ami-
noethylthio)adenosine-3′,5′-cyclic monophosphate (8-FcAMP) into
BeWo cells [74] suggest the possible involvement of a member of the
OATP transporter family.
Based upon the mRNA expression profile of OATP transporters in all
perfused placentas (Table 1), in vitro studies were carried out in several
A431 cell lines overexpressing OATP transporters to evaluate the in-
teraction of maraviroc and the inhibitors used with these uptake
transporters.
The accumulation assays revealed uptake of maraviroc by OATP1A2
and OATP1B3 when applied at low (65 nM) concentration. This effect
obviously remained hidden in the experimental setup of a recent study
that evaluated maraviroc in micromolar concentrations only using
OATP1B3-transfected HEK 293 cells [75].The number of OATP1A2
encoding mRNA transcripts (SLCO1A2) found in trophoblast cells was
comparable to the expression of MDR1 (ABCB1) and MRP1 (ABCC1),
while the expression of OATP1B3 encoding gene SLCO1B3 was one
order of magnitude lower. Expression of SLCO1B3 more than one order
of magnitude lower compared to that of SLCO1A2 was found also in the
perfused placental tissue and in isolated fetal trophoblast cells, in-
dicating that OATP1B3 can play a less important role in placental
transfer of maraviroc than does OATP1A2. Significant expression of
SLCO1A2 was revealed also in BeWo cells, thus indicating OATP1A2 to
be the OATP member most probably responsible for the observed up-
take of maraviroc to the BeWo cells (Fig. 2D). Decreased uptake was
then observed in the presence of elacridar, ritonavir, and higher con-
centration of maraviroc, the inhibitors of OATP1A2 as demonstrated in
inhibitory assays using OATPs overexpressing A431 cells (Fig. 5B).
Since verapamil is also a potent inhibitor of OATP1A2 [76], significant
decrease in maraviroc accumulation in BeWo cells in the presence of
verapamil can be also attributed to inhibited OATP1A2-mediated up-
take. These findings help to explain not only maraviroc’s behavior
during accumulation in BeWo cells, but also the drop of maraviroc le-
vels in maternal perfusates and their consequent increase after the
washout and pre-incubation period during placental perfusions, in
which inhibition of the OATP-mediated uptake obviously enables re-
leases of accumulated maraviroc from the tissue.
Identification of maraviroc as a substrate of other placental trans-
porters helps to explain its accelerated transport in the apical-to-baso-
lateral direction observed in BeWo cell monolayers. These indicate
vectorial transport of maraviroc provided by OATP1A2-mediated influx
in the apical membrane followed by MRP1-mediated efflux across the
basolateral membrane (Fig. 2A). Elacridar (GF) blocked only the api-
cally expressed OATP1A2 transporter, thereby decreasing the apical-to-
basolateral transport of maraviroc while having no effect on baso-
lateral-to-apical transport (Fig. 2B). In contrast, ritonavir, inhibiting
both OATP1A2 and MRP1, as shown in Fig. 5A,B, enabled higher per-
meability of maraviroc in the basolateral-to-apical direction (Fig. 2C).
Time-dependent accumulation of maraviroc was then shown in
fresh villous placental fragments representing primarily the situation in
syncytiotrophoblast as depicted in Fig. 6D. The absence of significant
effect of ritonavir or elacridar may be caused by inhibition not only of
OATP1A2 and MRP1, but also of MDR1 expressed in the apical mem-
brane (Fig. 6D). The contribution of OATP1B3 to this transport is
probably only marginal, because, in spite of the protein staining de-
scribed in the vasculosyncytial membrane [31], only very low expres-
sion was found in the placental tissue, as well as in isolated trophoblasts
and endothelial cells.
In summary, here we identified for the first time maraviroc as a
Fig. 6. Uptake of [3H]-MVC (65 nM) into fresh villous fragments of human term placenta.
A: Time-dependent accumulation of maraviroc in fresh villous placental fragments. B, C: Accumulation of maraviroc in presence of elacridar (GF, 2 μM), ritonavir
(RIT, 10 μM), and sulfasalazine (SLF, 100 μM) is shown at minute 30 (B) and at minute 90 (C) in presence of MK-571 (MK, 50 μM). D: Illustration of the experimental
setup showing transporters involved in transfer of maraviroc in syncytiotrophoblast. Data are presented as means ± SD (n ≥ 4). Statistical significance was
evaluated by Mann–Whitney test (*p≤ 0.05).
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substrate of three different transporters – MRP1, OATP1A2, and
OATP1B3 – while excluding its interaction with OATP2A1, OATP2B1,
OATP3A1, OATP4A1, and indirectly also with OCTN transporters.
Viewed in the context of MRP1 and OATP expression in human pla-
cental tissue, isolated trophoblasts, and fetal endothelial cells, our data
can contribute to a better understanding of maraviroc transplacental
pharmacokinetics and the drug’s safety during pregnancy. In addition
to the novel findings presented here, we question the generally ac-
cepted concept that considers MDR1 substrates always as compounds
with diminished maternal-to-fetal transfer. By the example of mar-
aviroc, we describe a situation wherein MDR1 activity was likely sur-
passed by the interplay of other placental transporters, the greatest
contribution to which we attribute to MRP1 and OATP1A2. In contrast
to the localization of MDR1 in the apical membrane, MRP1 was found
in basal membrane of polarized cells with the oppositely oriented
transport direction [77]. Basolateral localization of MRP1 has been
confirmed in trophoblast cells [17,18,78] and reported also in fetal
endothelial cells [18]. Therefore, we assume bidirectional flow of
maraviroc toward placental interstitium provided by the MRP1-medi-
ated efflux and further encouraged by OATP1A2- and, to a lower extent,
also by OATP1B3-mediated uptake. This theory actually corresponds
with our perfusion data and, consequently, it is not in conflict with the
low umbilical-cord-to-maternalblood ratio of maraviroc (0.33) reported
by Colbers et al. [42]. Obviously, the impact of transporters interplay
on transplacental drug transfer depends on the preferential affinity of
the drug to the particular transport proteins and on the transporter
expression profile across the pregnancy. Interestingly and in line with
our hypothesis, the well-known MRP1 substrate saquinavir showed low
penetration to fetus and retention within the placental tissue up to only
1.6 % in a study using an open-circuit placenta perfusion experiment in
the maternal-to-fetal direction [79]. Subsequently, it was found to be a
high affinity substrate of MDR1 and MRP2 [61], the transporters pro-
viding efflux on the apical microvillous membrane back to maternal
circulation and thereby overwhelming potential MRP1-mediated
transport of saquinavir in the opposite direction. Interestingly, reduc-
tion of saquinavir transport in the fetal-to-maternal direction by as
much as 43 % observed in other study, when MK-571 was added to the
perfusion buffer [80], could be explained as inhibition of MRP1 efflux
activity in fetal endothelial capillaries. Since MRP1 expression is sig-
nificantly increased by the end of gestation compared to at mid-gesta-
tion [81,82] while MDR1 is known to follow the opposite pattern [83],
the contribution of MRP1 might be increased by the end of gestation.
Indeed, Coles et al. have suggested that gestational-induced changes in
the transporters lead to greater uptake of saquinavir into mice placenta
at term [81]. Taking all these findings together, it seems that the MRP1-
mediated flux of maraviroc to the placenta is ensured in particular by
the end of pregnancy and that similar behavior might obviously be
expected in many other MRP1 substrates. Even though MRP1 is known
to transport several endogenous compounds, it is not yet clear what role
it fulfils when leading to the retention of its substrates within the pla-
cental tissue. We could speculate that by the end of pregnancy the inner
placental tissue might serve as space for disposal storage and additional
protection of the fetus and its mother shortly before delivery, during
which the organ is released. This hypothesis might be further supported
by findings of high levels of methylmercury in placentas of women
exposed to this toxin during pregnancy, as it, too, recently was identi-
fied as an MRP1 substrate [84,85]. Detailed studies would be needed to
consider the possibility that additional drugs described as MRP1 sub-
strates could be retained in human placental tissue when possessing
lower affinity to efflux transporters localized in the trophoblast mi-
crovillous membrane. Importantly, when evaluating the maternal-to-
fetal transfer of drugs and other xenobiotics, the involvement of addi-
tional placental transporters and their interplay affecting the perme-
ability of an investigated compound must be borne in mind and con-
sidered critically.
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